Pay in 4 interest-free payments of $36.25 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
InChi: InChI=1S/C28H24N4O3/c33-25-19-26(28-29-31-32-30-28)35-27-22(10-6-11-24(25)27)15-12-21-13-16-23(17-14-21)34-18-5-4-9-20-7-2-1-3-8-20/h1-3
Analysis of the inhibition kinetics by double-reciprocal plot demonstrates that galangin inhibits CYP1A1 activity in a noncompetitive manner
InChi: InChI=1S/C22H38O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(24)28-16-17(23)21-19(25)20(26)22(27)29-21/h17
13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2
Aficamten - CAS# 2364554-48-1 Catalog No.:M33502-2 InChi: InChI=1S/C28H24N4O3/c33-25-19-26(28-29-31-32-30-28)35-27-22(10-6-11-24(25)27)15-12-21-13-16-23(17-14-21)34-18-5-4-9-20-7-2-1-3-8-20/h1-3Aficamten, CAS No. 2364554 48 1, also known as CK 3773274 and CK 274, is a Next Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. Aficamten was designed to provide a predicted human half life (t1 2) appropriate for once a day (qd) dosing, to reach steady state within two weeks, to have no substantial cytochrome P450 induction or inhibition, and to have a wide therapeutic window in vivo with a clear pharmacokinetic
US$ 447.50
US$ 20.00
US$ 30.00
US$ 40.00
US$ 30.00
US$ 397.50
US$ 28.00
US$ 26.00
US$ 20.00
US$ 22.00
US$ 15.00